Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study

SIMPLE SUMMARY: Despite the emergence of new therapies during the last decade, metastatic castration-resistant prostate cancer (mCRPC) remains fatal. Recent work showed that the timing of treatment initiation seems critical for patient outcomes. Thus, it is key to identify factors that can help in d...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancers (Basel)
Glavni autori: Delanoy, Nicolas, Robbrecht, Debbie, Eisenberger, Mario, Sartor, Oliver, de Wit, Ronald, Mercier, Florence, Geffriaud-Ricouard, Christine, de Bono, Johann, Oudard, Stéphane
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2021
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8002173/
https://ncbi.nlm.nih.gov/pubmed/33805793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13061284
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items